Description
About GLP-3 RT (research peptide)
GLP-3 RT is Velora Research’s branded supply of GLP-3 RT, a synthetic 39-amino-acid peptide that has been studied as the first triple-receptor agonist of GLP-1, GIP, and glucagon. Researchers buy GLP-3 RT in lyophilized form for in vitro and preclinical investigations into metabolic regulation, lipid handling, and energy-expenditure pathways.
Every vial of GLP-3 RT is manufactured under documented production protocols and independently verified by a third-party laboratory using high-performance liquid chromatography (HPLC) and mass spectrometry. The Certificate of Analysis for each batch is published on our site and linked directly from the product page so qualified researchers can confirm identity, purity, and molecular integrity before placing the compound into a study.
Mechanism of action — what the published research describes
GLP-3 RT (LY3437943, originally developed by Eli Lilly) is a long-acting fatty-acid-conjugated peptide that engages three incretin and metabolic receptors simultaneously:
- GLP-1 receptor — the same target as semaglutide and the GLP-1 component of tirzepatide; observed in published research to influence glycemic regulation pathways.
- GIP receptor — shared with the second component of tirzepatide; described in preclinical literature as contributing to nutrient-handling pathways.
- Glucagon receptor — the receptor unique to GLP-3 RT among current incretin-class research peptides; described in published trial data as contributing to energy-expenditure pathways.
Published Phase 2 readouts (NEJM 2023; ClinicalTrials.gov NCT04881760) reported the largest mean body-weight reductions observed to date in incretin-class trials at peak dose, while open-label Phase 3 work in the TRIUMPH program is ongoing. GLP-3 RT is supplied solely as a research compound to support in vitro mechanism studies, receptor-binding assays, and preclinical models — it is not intended for and is not legal to use in humans or animals.
Key specifications:
| Attribute | Specification |
| Research name | GLP-3 RT (research peptide) |
| Developmental name | LY3437943 |
| Receptor activity | Triple agonist — GLP-1, GIP, glucagon |
| Available sizes | 10mg, 20mg, 30mg |
| Form | Lyophilized white powder |
| Purity | ≥99.0% (HPLC verified) |
| Molecular formula | C316H481F3N94O101 |
| Molecular weight | ~6758.22 g/mol |
| Storage | Lyophilized: -20°C, sealed, dark, dry. Reconstituted: 2-8°C, use within research-protocol window. |
| Verification | Independent third-party HPLC + mass spectrometry per batch |
| COA access | Batch-specific COA published on /coas/ and linked to product page |
Available sizes & GLP-3 RT price
GLP-3 RT is available in three vial sizes so researchers can match purchase volume to study scope without overstocking a single batch:
| Vial size | Price (USD) | Best for |
| 10mg | $81.00 | Pilot studies, receptor-binding assays, single-protocol pilots |
| 20mg | Listed at checkout | Multi-arm preclinical work, repeat-dose protocols |
| 30mg | $170.00 | Long-running protocols, multi-lab studies, cost-per-mg efficiency |
The GLP-3 RT price per milligram drops at the 30mg tier, which makes the larger vial the typical choice for studies running longer than a single pilot. All GLP-3 RT orders over $200 ship free within the United States via 2-day delivery; international orders are accepted in accordance with applicable research regulations.
Why qualified researchers buy GLP-3 RT from Velora Research
Vendor selection in the research-peptide space is a trust problem, not a pricing problem. Five things separate Velora Research from the field:
- Batch-level third-party COA. Every lot is verified by an independent analytical lab using HPLC and mass spectrometry; the COA is downloadable from the product page and tied to the batch number printed on the vial.
- ≥99% HPLC-verified purity. Identity, purity, and molecular integrity are confirmed before any batch is released for sale.
- Documented production protocols. Lyophilized under controlled conditions, sealed in inert atmosphere, traceable from synthesis through shipment.
- US-based 2-day shipping with cold-chain handling. Free over $200, with all orders processed within 1–2 business days.
- Compliance-first sales policy. Sales are restricted to qualified laboratories, institutions, and research professionals. Every order acknowledges the research-use-only terms prior to checkout.
Reconstitution & storage guidance (research use)
GLP-3 RT ships as a lyophilized powder. For in vitro studies, researchers typically reconstitute with bacteriostatic water (0.9% benzyl alcohol) at a concentration that fits the assay protocol. A common pilot ratio for a 10mg vial is 2 mL of BAC water, yielding a 5 mg/mL solution — adjust per your study design.
- Pre-reconstitution: store sealed at -20°C in a dry, dark environment. Avoid freeze-thaw cycles.
- Post-reconstitution: refrigerate at 2-8°C and use within the stability window established by the study protocol.
- Handling: always reconstitute and aliquot in sterile lab conditions with appropriate PPE.
Velora Research supplies bacteriostatic water as a separate product. Please refer to the published peer-reviewed literature for protocol-specific reconstitution and handling parameters.
GLP-3 RT vs. tirzepatide vs. semaglutide — research-context comparison
Researchers evaluating GLP-3 RT for purchase often compare it to other incretin-class peptides. Summary of how the three differ at the receptor level, drawn from published trial readouts:
| Attribute | Semaglutide | Tirzepatide | GLP-3 RT |
| Receptor targets | GLP-1 | GLP-1, GIP | GLP-1, GIP, glucagon |
| Class | Single-receptor agonist | Dual-receptor agonist | Triple-receptor agonist |
| Trial stage (as of 2026) | Marketed | Marketed | Phase 3 (TRIUMPH program) |
| Reported peak weight reduction in trials | ~14-15% | ~20-22% | ~24% (Phase 2 peak dose) |
| Half-life | ~7 days | ~5 days | ~6 days |
| Dosing in research literature | Weekly | Weekly | Weekly |
Figures are drawn from published preclinical and clinical literature and are provided strictly for research-context comparison. GLP-3 RT is supplied as a research peptide for in vitro and preclinical investigation only — not as a therapeutic product.
